European Journal of Cancer
Volume 42, Issue 15 , Pages 2472-2479, October 2006

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound☆

  • Michele Lamuraglia

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • Section of Internal Medicine, Department of Internal Medicine and Public Medicine, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy
    • ,
  • Bernard Escudier

      Affiliations

    • Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Linda Chami

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Brian Schwartz

      Affiliations

    • Bayer Pharmaceuticals Corporation, West Haven CT 06516, USA
    • ,
  • Jérome Leclère

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Alain Roche

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • ,
  • Nathalie Lassau

      Affiliations

    • Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    • Corresponding Author InformationCorresponding author: Tel.: +33 1 42 11 60 14; fax: +33 1 42 11 60 29.

Received 15 February 2006; received in revised form 18 April 2006; accepted 20 April 2006.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    • ☆ This work was presented at the ASCO and ECCO meetings in 2005.

    PII: S0959-8049(06)00607-1

    doi:10.1016/j.ejca.2006.04.023

    Refers to erratum:

    • Erratum to “To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound” [European Journal of Cancer, 42 (2006) 2472–2479]

      Michele Lamuraglia, Bernard Escudier, Linda Chami, Brian Schwartz, Jérome Leclère, Alain Roche, Nathalie Lassau
      European Journal of Cancer May 2007 (Vol. 43, Issue 8, Page 1336)

    European Journal of Cancer
    Volume 42, Issue 15 , Pages 2472-2479, October 2006